FIELD: chemistry.
SUBSTANCE: invention relates to analytical chemistry and specifically to monitoring efficiency of antiaggregant therapy during treatment of cardio-vascular diseases. Acetalsalicylic acid (ASA) still remains the main anti-thrombotic drug when treating aggravation of coronary heart disease. That said, 4-45% patients are biochemically resistant to its effect. The proposed method for quantitative determination of anti-thrombotic effect of acetalsalicylic acid in vitro is based on measuring parametres of induced thrombocyte aggregation directly in whole blood using an impedance method before and after incubation of samples with acetalsalicylic acid.
EFFECT: increased sensitivity, accuracy, reproducibility, cutting on analysis time.
1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DETERMINING PLATELET RESISTANCE TO ACETYLSALICYLIC ACID | 2013 |
|
RU2538219C2 |
| METHOD OF INDIVIDUAL PROGNOSIS OF CLINICAL EFFECTIVENESS OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME | 2016 |
|
RU2639772C1 |
| METHOD FOR ESTIMATING CLINICAL EFFECTIVENESS OF ANTIAGGREGANT THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME | 2011 |
|
RU2486523C1 |
| METHOD FOR THROMBOCYTE AGGREGATION ACTIVITY DETERMINATION FOR PATIENTS WITH ACUTE CORONARY SYNDROME | 2016 |
|
RU2619858C1 |
| METHOD FOR RAPID DIAGNOSIS OF RESISTANCE AND SUSCEPTIBILITY TO ACETYLSALICYLIC ACID | 2015 |
|
RU2578428C1 |
| METHOD FOR QUANTITATIVE ASSESSMENT OF THROMBOCYTE AGGREGATION ACTIVITY IN PATIENTS WITH NEW CORONAVIRAL INFECTION | 2021 |
|
RU2760095C1 |
| HAEMOSTASIS SYSTEM CORRECTOR MANIFESTING INHIBITORY ACTION ON ADHESIVE AGGREGATIVE FUNCTION OF THROMBOCYTES TO PREVENT PATHOLOGICAL THROMBOSIS | 2008 |
|
RU2373929C1 |
| METHOD OF ASSESSING THE EFFICIENCY OF ANTI-CLEGGANT MEDICINAL PRODUCT IN WHOLE PERIPHERAL BLOOD SAMPLES | 2022 |
|
RU2800671C1 |
| METHOD OF DETERMINING THROMBOCYTE SENSITIVITY TO ACETYLSALICYLIC ACID | 2018 |
|
RU2699569C1 |
| AGENT POSSESSING ANTIAGGREGANT ACTIVITY | 2019 |
|
RU2696583C1 |
